Abstract: The present invention relates to a method of treating a patient for a condition where blood flow to a tissue or organ is interrupted. This method involves administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1? inactivation in cells affected by the condition, thereby treating the patient for the condition. Also disclosed is a method of treating a tumor in a patient. In addition, the present invention relates to methods of identifying compounds as candidate drugs for treatment of hypoxic conditions and for treating tumors in a subject.

Abstract: The invention relates to a method of using an inducible transgene in a cell, where the inducible transgene expresses a gene product having activity on a cell death or cell survival pathway. The method includes exposing the cell to an agent that is capable of inducing the inducible transgene but also has direct activity on a cell death or cell survival pathway, said exposing being carried out in a manner effective to induce expression of the transgene while substantially minimizing said direct activity of the agent. Host cells and kits for carrying out the method are also disclosed.

Abstract: The present invention relates to a method of treating a patient for a condition where blood flow to a tissue or organ is interrupted. This method involves administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1? inactivation in cells affected by the condition, thereby treating the patient for the condition. Also disclosed is a method of treating a tumor in a patient. In addition, the present invention relates to methods of identifying compounds as candidate drugs for treatment of hypoxic conditions and for treating tumors in a subject.

Abstract: The invention includes methods for delivering therapeutic agents to a patient through administration of herpesvirus amplicon particles generated by a cell that stably express herpes simplex virus (HSV) immediate early 3 (IE3) gene.